| 1 |
34155339 | Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells. | 2022 Apr |
1 |
| 2 |
35059891 | A possible case of carbamazepine-induced renal phospholipidosis mimicking Fabry disease. | 2022 Mar |
1 |
| 3 |
35242579 | Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort. | 2022 Jun |
1 |
| 4 |
35512362 | Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). | 2022 May 5 |
1 |
| 5 |
32963035 | Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. | 2021 Oct |
1 |
| 6 |
32994552 | Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. | 2021 Jan |
1 |
| 7 |
33460651 | Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry. | 2021 Jan-Jun |
2 |
| 8 |
33477028 | Globotriaosylceramide-related biomarkers of fabry disease identified in plasma by high-performance thin-layer chromatography - densitometry- mass spectrometry. | 2021 Feb 8 |
1 |
| 9 |
33531072 | DNA methylation impact on Fabry disease. | 2021 Feb 2 |
1 |
| 10 |
33572752 | The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field. | 2021 Jan 29 |
1 |
| 11 |
33577039 | Arterial involvement in Fabry disease: state of the art and future diagnostic purposes. | 2021 Jan |
1 |
| 12 |
33592213 | Targeted lipidomics reveals associations between serum sphingolipids and insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp. | 2021 Mar |
1 |
| 13 |
33661535 | Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells. | 2021 Jul |
1 |
| 14 |
33721270 | Fabry Disease: The Current Treatment Landscape. | 2021 Apr |
1 |
| 15 |
33738082 | Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. | 2021 Mar |
1 |
| 16 |
33753109 | Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer. | 2021 May 15 |
1 |
| 17 |
33768330 | Pathology and pathogenic pathways in fabry nephropathy. | 2021 Sep |
1 |
| 18 |
33968642 | Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations. | 2021 Apr |
1 |
| 19 |
33968643 | Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review. | 2021 Apr |
1 |
| 20 |
34073185 | Therapeutic Uses of Bacterial Subunit Toxins. | 2021 May 26 |
1 |
| 21 |
34204583 | Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease. | 2021 Jun 17 |
1 |
| 22 |
34284652 | Ion channels and pain in Fabry disease. | 2021 Jan-Dec |
1 |
| 23 |
34422789 | Dual DNA Transfection Using 1,6-Hexanedithiol-Conjugated Maleimide-Functionalized PU-PEI600 For Gene Correction in a Patient iPSC-Derived Fabry Cardiomyopathy Model. | 2021 |
1 |
| 24 |
34576250 | Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. | 2021 Sep 18 |
1 |
| 25 |
34609404 | Fabry disease - current data and therapeutic approaches. | 2021 Jan-Mar |
1 |
| 26 |
34631425 | Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease. | 2021 Dec |
1 |
| 27 |
34748189 | Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease. | 2021 Nov |
1 |
| 28 |
34885938 | A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3). | 2021 Dec 3 |
1 |
| 29 |
34917096 | Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation. | 2021 |
1 |
| 30 |
31778673 | High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. | 2020 Feb |
1 |
| 31 |
31939530 | Fabry disease: genetics, pathology, and treatment. | 2020 Jan 13 |
1 |
| 32 |
32183018 | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses. | 2020 Mar 13 |
1 |
| 33 |
32198894 | Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). | 2020 Aug |
1 |
| 34 |
32248228 | Catfish egg lectin affects influx and efflux rates of sunitinib in human cervical carcinoma HeLa cells. | 2020 Sep 28 |
1 |
| 35 |
32292674 | An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene. | 2020 Mar 13 |
1 |
| 36 |
32296648 | Verotoxin Receptor-Based Pathology and Therapies. | 2020 |
1 |
| 37 |
32306353 | Preparation of Fluorescent Recombinant Shiga Toxin B Subunit and Its Application to Flow Cytometry. | 2020 |
2 |
| 38 |
32523894 | Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor. | 2020 |
1 |
| 39 |
32532136 | Kidney Transplant in Fabry Disease: A Revision of the Literature. | 2020 Jun 10 |
2 |
| 40 |
32612933 | Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. | 2020 Sep |
1 |
| 41 |
32661622 | Fabry disease: where are we now? | 2020 Nov |
1 |
| 42 |
32673369 | A portable and high-sensitivity optical sensing system for detecting fluorescently labeled enterohaemorrhagic Escherichia coli Shiga toxin 2B-subunit. | 2020 |
1 |
| 43 |
32699723 | Rare Etiology of Renal Failure in a 25-Year-Old Caucasian Man: Fabry Disease With a Novel Mutation of GLA Gene. | 2020 Jul 11 |
1 |
| 44 |
32775495 | AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. | 2020 Sep 11 |
1 |
| 45 |
32854306 | Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles. | 2020 Aug 25 |
1 |
| 46 |
33205006 | Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation. | 2020 Nov |
1 |
| 47 |
29875425 | Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients. | 2019 Jan |
2 |
| 48 |
30660999 | A CRISPR Screen Identifies LAPTM4A and TM9SF Proteins as Glycolipid-Regulating Factors. | 2019 Jan 25 |
1 |
| 49 |
30853972 | A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease. | 2019 |
1 |
| 50 |
30972193 | Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. | 2019 |
2 |